0.32  0.02 (6.67%)		08-14 16:00
Open: 0.395 High: 0.8699 Volume: 100		Pre. Close: 0.3 Low: 0.32 Market Cap: 13(M)

Short term
Mid term
Targets	6-month :	0.62	1-year :	1.01
Resists	First :	0.53	Second :	0.86
Pivot price	0.31
Supports	First :	0	Second :	0
MAs	MA(5) :	0.3	MA(20) :	0.31
	MA(100) :	0.44	MA(250) :	1.22
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	1.1	D(3) :	0.9
RSI	RSI(14): 49.3
52-week	High :	2.9	Low :	0

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ANEB ] has closed below upper band by 46.7%. Bollinger Bands are 81.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.4 - 0.4	0.4 - 0.4
Low:	0.32 - 0.32	0.32 - 0.32
Close:	0.32 - 0.32	0.32 - 0.32

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.

Thu, 23 Jul 2026
Stabilis Solutions And 2 Other High-Quality Penny Stocks For Savvy Investors - simplywall.st

Fri, 06 Feb 2026
Anebulo Pharmaceuticals stock plunges after announcing Nasdaq delisting plans - Investing.com

Thu, 08 Aug 2024
PBM Stock Price and Chart — NASDAQ:PBM - TradingView

Fri, 06 Oct 2023
Anebulo Pharmaceuticals Announces New CEO - BioSpace

Sat, 11 Feb 2023
Daniel Schneeberger Net Worth (2026) - GuruFocus

Mon, 28 Nov 2022
Simon Allen Net Worth (2026) - GuruFocus

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: OTC
Sector: Healthcare
Industry: Biotechnology
Shares Out	41 (M)
Shares Float	24 (M)
Held by Insiders	40.8 (%)
Held by Institutions	0 (%)
Shares Short	146 (K)
Shares Short P.Month	58 (K)

EPS	-0.19
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.18
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-45.1 %
Return on Equity (ttm)	-69.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-6 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-1.78
PEG Ratio	0
Price to Book value	1.68
Price to Sales	0
Price to Cash Flow	-2.24

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.